Sun Pharmaceutical rose 6.78% to ₹1,730.20 after signing definitive agreement to acquire Organon & Co. in an all-cash $11.75 billion deal. Organon shareholders will receive $14 per share. The acquisition will expand Sun Pharma into biosimilars, women's health and branded medicines, creating a combined $12.4 billion revenue pharma entity with presence in 150 countries.